Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2015 16:02 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Second Quarter 2015 Financial Results and Recent Highlights

First Clinical Data on Glutaminase Inhibitor CB-839 in Solid and Hematologic Malignancies Immuno-oncology Program with Arginase Inhibitor CB-1158 on Track for Preclinical Data Release in Fourth...
August 05, 2015 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Second Quarter 2015 Financial Results on Monday, August 10, 2015

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
June 23, 2015 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Selects Immuno-Oncology Clinical Candidate CB-1158, an Oral Arginase Inhibitor for the Treatment of Cancer

Similar mechanism of action to IDO inhibitors Potential to combine with anti-CTLA-4, anti-PD-1 and other immuno-oncology therapies SOUTH SAN FRANCISCO, Calif., June 23, 2015 (GLOBE NEWSWIRE) --...
June 16, 2015 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present at the JMP Securities Life Sciences Conference 2015

SOUTH SAN FRANCISCO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
June 11, 2015 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Acute Leukemias at the 20th Congress of the European Hematology Association

Promising Clinical Activity With Early Signs of Biologic Activity, Tolerability, and Durability Clinical Response Reported With Single Agent CRi in AML SOUTH SAN FRANCISCO, Calif., June 11, 2015...
May 30, 2015 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Reports Phase I Data for CB-839 in Patients with Solid Tumors at the 2015 American Society of Clinical Oncology

Data Support Initiation of Multiple Solid Tumor Expansion Cohorts Calithera to Host Investor Webcast on May 30, 2015 at 6:30 p.m. CT SOUTH SAN FRANCISCO, Calif., May 30, 2015 (GLOBE...
May 21, 2015 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Reports Initial Phase I Data for CB-839 in Patients with Acute Leukemias

SOUTH SAN FRANCISCO, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics,...
May 07, 2015 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports First Quarter 2015 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
May 07, 2015 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference - Revised Date of Presentation

SOUTH SAN FRANCISCO, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
May 06, 2015 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...